H.C. Wainwright has initiated coverage of BioPharmX (NYSE MKT:BPMX) with a “buy” rating and $3 price target. The stock closed at 99 cents on Wednesday.
“We expect BioPharmX to experience significant growth in the mid-term with a five-year revenue CAGR of 135% between fiscal 2017 and fiscal 2022,” writes analyst Swayampakula Ramakanth".
H.C. Wainwright - Meet Our Analysts
Ed Arce
Managing Director, Senior Healthcare Analyst
Mr. Arce holds a Master of Science in Finance (MSF) degree from Boston College, as well as an MBA and a B.S. in Civil Engineering, both from Florida International University (FIU). Mr. Arce is also a Board-licensed Professional Engineer (P.E.), and a Level III CFA candidate.
Mark Breidenbach, Ph.D
Managing Director, Senior Healthcare Analyst
Mark holds a Ph.D. in Molecular & Cellular Physiology from Stanford University and an M.Phil. in Molecular Biophysics & Biochemistry from Yale University where he studied the structural biochemistry of clostridial neurotoxins. Additionally, Mark conducted postdoctoral studies in chemical glycobiology at the University of California Berkeley’s Department of Chemistry, and holds a B.A. in Biochemistry from Cornell University.
Yi Chen, Ph.D., CFA
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Dr. Chen obtained his Ph.D. in biochemistry from the City University of New York in February 2007, and B.S. in Biophysics from Fudan University in July 1999. He is a Chartered Financial Analyst (CFA) charter holder.
Amit Dayal
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Mr. Dayal holds an MBA from Babson College, an M.Com from University of Delhi and a B.Com (Hons) from University of Delhi.
Kevin Dede, CFA
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Andrew Fein
Managing Director, Senior Healthcare Analyst
Andrew received his Bachelor of Arts degree from Yale University.
Heiko Ihle, CFA
Managing Director, Senior Metals & Mining Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Raghuram Selvaraju, Ph.D.
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Dr. Selvaraju earned a Ph.D. in molecular neuroscience and cellular immunology as well as an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University.
Carol Werther
Managing Director, Senior Healthcare Analyst
Ms. Werther earned her MBA in Finance at New York University‘s Stern School of Business. In addition, she has a M.S. and B.S. in Nutrition Sciences from The University of Alabama in Birmingham and Cornell University, respectively.
Swayampakula Ramakanth, Ph.D.
Managing Director, Senior Healthcare Analyst
Dr. Ramakanth earned his doctorate in Pharmacology/ Toxicology by characterizing a novel gene for a drug metabolizing enzyme. His expertise includes drug metabolism, molecular biology and pre-clinical drug development. Dr. Ramakanth has presented at various regional and international conferences and published in peer-reviewed journals. Dr. Ramakanth has a Ph.D. in Pharmacology/Toxicology from the University of Utah, a MBA from Rutgers University, M.S. in Pharmaceutics from Auburn University, and B. Pharm (Hons.) from BITS, India. He held a post-doctoral fellowship at the University of Texas MD Anderson Cancer Center.
H.C. Wainwright has initiated coverage of BioPharmX
“We believe that the U.S. market for FBC treatments could reach $400-million per year, and currently we expect sales of Violet to grow from $863,000 in fiscal 2017 to $16.4-million in 2025,” Mr. Ramakanth said.
BPX-03, a prescription molecular iodine product designed to treat severe FBC, has successfully completed a placebo-controlled Phase 2 study and is expected to enter a pivotal Phase 3 study in 2017. “If successfully developed, we believe BPX-03 could be launched in fiscal 2020 and achieve risk-adjusted revenues of $20.7-million by 2025,” he added.
“We expect BioPharmX to experience significant growth in the mid-term with a five-year revenue CAGR of 135% between fiscal 2017 and fiscal 2022,” writes analyst Swayampakula Ramakanth".
H.C. Wainwright - Meet Our Analysts
Ed Arce
Managing Director, Senior Healthcare Analyst
Mr. Arce holds a Master of Science in Finance (MSF) degree from Boston College, as well as an MBA and a B.S. in Civil Engineering, both from Florida International University (FIU). Mr. Arce is also a Board-licensed Professional Engineer (P.E.), and a Level III CFA candidate.
Mark Breidenbach, Ph.D
Managing Director, Senior Healthcare Analyst
Mark holds a Ph.D. in Molecular & Cellular Physiology from Stanford University and an M.Phil. in Molecular Biophysics & Biochemistry from Yale University where he studied the structural biochemistry of clostridial neurotoxins. Additionally, Mark conducted postdoctoral studies in chemical glycobiology at the University of California Berkeley’s Department of Chemistry, and holds a B.A. in Biochemistry from Cornell University.
Yi Chen, Ph.D., CFA
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Dr. Chen obtained his Ph.D. in biochemistry from the City University of New York in February 2007, and B.S. in Biophysics from Fudan University in July 1999. He is a Chartered Financial Analyst (CFA) charter holder.
Amit Dayal
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Mr. Dayal holds an MBA from Babson College, an M.Com from University of Delhi and a B.Com (Hons) from University of Delhi.
Kevin Dede, CFA
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Andrew Fein
Managing Director, Senior Healthcare Analyst
Andrew received his Bachelor of Arts degree from Yale University.
Heiko Ihle, CFA
Managing Director, Senior Metals & Mining Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Raghuram Selvaraju, Ph.D.
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.
Dr. Selvaraju earned a Ph.D. in molecular neuroscience and cellular immunology as well as an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University.
Carol Werther
Managing Director, Senior Healthcare Analyst
Ms. Werther earned her MBA in Finance at New York University‘s Stern School of Business. In addition, she has a M.S. and B.S. in Nutrition Sciences from The University of Alabama in Birmingham and Cornell University, respectively.
Swayampakula Ramakanth, Ph.D.
Managing Director, Senior Healthcare Analyst
Dr. Ramakanth earned his doctorate in Pharmacology/ Toxicology by characterizing a novel gene for a drug metabolizing enzyme. His expertise includes drug metabolism, molecular biology and pre-clinical drug development. Dr. Ramakanth has presented at various regional and international conferences and published in peer-reviewed journals. Dr. Ramakanth has a Ph.D. in Pharmacology/Toxicology from the University of Utah, a MBA from Rutgers University, M.S. in Pharmaceutics from Auburn University, and B. Pharm (Hons.) from BITS, India. He held a post-doctoral fellowship at the University of Texas MD Anderson Cancer Center.
H.C. Wainwright has initiated coverage of BioPharmX
“We believe that the U.S. market for FBC treatments could reach $400-million per year, and currently we expect sales of Violet to grow from $863,000 in fiscal 2017 to $16.4-million in 2025,” Mr. Ramakanth said.
BPX-03, a prescription molecular iodine product designed to treat severe FBC, has successfully completed a placebo-controlled Phase 2 study and is expected to enter a pivotal Phase 3 study in 2017. “If successfully developed, we believe BPX-03 could be launched in fiscal 2020 and achieve risk-adjusted revenues of $20.7-million by 2025,” he added.
